Becton, Dickinson and Company $BDX Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 6.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 58,385 shares of the medical instruments supplier’s stock after selling 4,350 shares during the quarter. Yousif Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $11,875,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in Becton, Dickinson and Company by 71.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after acquiring an additional 34,437 shares during the period. Transcend Capital Advisors LLC grew its position in Becton, Dickinson and Company by 88.2% in the third quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock worth $1,084,000 after acquiring an additional 2,715 shares during the period. Belpointe Asset Management LLC purchased a new position in Becton, Dickinson and Company in the third quarter worth approximately $650,000. Finally, Vanguard Group Inc. grew its position in Becton, Dickinson and Company by 0.5% in the third quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after acquiring an additional 147,041 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BDX. Royal Bank Of Canada set a $172.00 price objective on Becton, Dickinson and Company in a research report on Tuesday, February 10th. Argus lowered their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 23rd. Wells Fargo & Company lowered their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 11th. Finally, TD Cowen raised their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $191.62.

Becton, Dickinson and Company Stock Up 1.3%

Becton, Dickinson and Company stock opened at $156.98 on Thursday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a market cap of $44.70 billion, a PE ratio of 25.61, a P/E/G ratio of 11.20 and a beta of 0.29. The stock’s fifty day moving average is $172.86 and its two-hundred day moving average is $185.81.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period last year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,713 shares of company stock worth $536,881 in the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.